The Korean Journal of Physiology and Pharmacology

The Korean Society of Pharmacology (대한약리학회)
권호 표지
DOI QR코드

DOI QR Code

Bordetella bronchiseptica is a potent and safe adjuvant that enhances the antigen-presenting capability of dendritic cells

  • Lee, You-Jeong (College of Veterinary Medicine, Jeju National University) ;
  • Han, Yong (College of Veterinary Medicine, Jeju National University) ;
  • Joo, Hong-Gu (College of Veterinary Medicine, Jeju National University)
  • Received : 2019.07.16
  • Accepted : 2019.11.05
  • Published : 2020.01.01
Download PDF
⟨ Previous Next ⟩

Abstract

We previously demonstrated that Bordetella bronchiseptica (B. bronchiseptica) antigen (Ag) enhances the Mycoplasma hyopneumoniae Ag-specific immune response. The focus of this study was whether acellular bacterin of B. bronchiseptica could be used as an adjuvant to increase antigen-presenting capability of dendritic cells (DCs) by increasing the level of activation. The metabolic activity of DCs was increased by B. bronchiseptica, similar to lipopolysaccharide (LPS). Flow cytometry analysis revealed that B. bronchiseptica increases the expression of major histocompatibility complex class-2, cluster of differentiation (CD)40, CD54, and CD86 which are closely related to DC-mediated immune responses. B. bronchiseptica enhanced the production of cytokines related to adaptive immune responses. Furthermore, the survival rate of B. bronchiseptica-injected groups was 100% at 15 and 20 mg/kg doses, whereas that of LPS-injected groups was only 20%, 0% at 15 and 20 mg/kg doses respectively, and so B. bronchiseptica is likely to be safer than LPS. Taken together, these results indicate that B. bronchiseptica can be used as an adjuvant to enhance the antigen-presenting capability of DCs. B. bronchiseptica is a candidate for producing vaccines, especially in case of DC-mediating efficacy and safety demands. This study provides researchers and clinicians with valuable information regarding the usage of B. bronchiseptica as a safe bacteria-derived immunostimulating agent for developing efficient vaccines.

Keywords

References

  1. Karch CP, Burkhard P. Vaccine technologies: from whole organisms to rationally designed protein assemblies. Biochem Pharmacol. 2016;120:1-14. https://doi.org/10.1016/j.bcp.2016.05.001
  2. Marciani DJ. Vaccine adjuvants: role and mechanisms of action in vaccine immunogenicity. Drug Discov Today. 2003;8:934-943. https://doi.org/10.1016/S1359-6446(03)02864-2
  3. Del Giudice G, Rappuoli R, Didierlaurent AM. Correlates of adjuvanticity: a review on adjuvants in licensed vaccines. Semin Immunol. 2018;39:14-21. https://doi.org/10.1016/j.smim.2018.05.001
  4. Coffman RL, Sher A, Seder RA. Vaccine adjuvants: putting innate immunity to work. Immunity. 2010;33:492-503. https://doi.org/10.1016/j.immuni.2010.10.002
  5. Dunne A, Mielke LA, Allen AC, Sutton CE, Higgs R, Cunningham CC, Higgins SC, Mills KH. A novel TLR2 agonist from Bordetella pertussis is a potent adjuvant that promotes protective immunity with an acellular pertussis vaccine. Mucosal Immunol. 2015;8:607-617. https://doi.org/10.1038/mi.2014.93
  6. Wangoo A, Brown IN, Marshall BG, Cook HT, Young DB, Shaw RJ. Bacille Calmette-Guerin (BCG)-associated inflammation and fibrosis: modulation by recombinant BCG expressing interferon-gamma (IFN-gamma). Clin Exp Immunol. 2000;119:92-98. https://doi.org/10.1046/j.1365-2249.2000.01100.x
  7. Filardi MJ, Codish SD, Civerchia L, Howard RK, McKneally MF. Toxicity of intrapleural Bacillus Calmette-Guerin treatment in animals. Cancer Res. 1979;39:3673-3676.
  8. Gordon S, Keshav S, Stein M. BCG-induced granuloma formation in murine tissues. Immunobiology. 1994;191:369-377. https://doi.org/10.1016/S0171-2985(11)80442-0
  9. Fedele G, Celestino I, Spensieri F, Frasca L, Nasso M, Watanabe M, Remoli ME, Coccia EM, Altieri F, Ausiello CM. Lipooligosaccharide from Bordetella pertussis induces mature human monocyte-derived dendritic cells and drives a Th2 biased response. Microbes Infect. 2007;9:855-863. https://doi.org/10.1016/j.micinf.2007.03.002
  10. Samore MH, Siber GR. Pertussis toxin enhanced IgG1 and IgE responses to primary tetanus immunization are mediated by interleukin-4 and persist during secondary responses to tetanus alone. Vaccine. 1996;14:290-297. https://doi.org/10.1016/0264-410X(95)00201-B
  11. Zhao Z, Wang C, Xue Y, Tang X, Wu B, Cheng X, He Q, Chen H. The occurrence of Bordetella bronchiseptica in pigs with clinical respiratory disease. Vet J. 2011 188:337-340. https://doi.org/10.1016/j.tvjl.2010.05.022
  12. Goodnow RA. Biology of Bordetella bronchiseptica. Microbiol Rev. 1980;44:722-738. https://doi.org/10.1128/mr.44.4.722-738.1980
  13. Chanter N, Magyar T, Rutter JM. Interactions between Bordetella bronchiseptica and toxigenic Pasteurella multocida in atrophic rhinitis of pigs. Res Vet Sci. 1989;47:48-53. https://doi.org/10.1016/S0034-5288(18)31230-X
  14. Horiguchi Y. Swine atrophic rhinitis caused by pasteurella multocida toxin and bordetella dermonecrotic toxin. Curr Top Microbiol Immunol. 2012;361:113-129. https://doi.org/10.1007/82_2012_206
  15. Siciliano NA, Skinner JA, Yuk MH. Bordetella bronchiseptica modulates macrophage phenotype leading to the inhibition of CD4+ T cell proliferation and the initiation of a Th17 immune response. J Immunol. 2006177:7131-7138. https://doi.org/10.4049/jimmunol.177.10.7131
  16. Yim SH, Hahn TW, Joo HG. Bordetella bronchiseptica antigen enhances the production of Mycoplasma hyopneumoniae antigenspecific immunoglobulin G in mice. J Vet Sci. 2017;18:327-332. https://doi.org/10.4142/jvs.2017.18.3.327
  17. Gallucci S, Lolkema M, Matzinger P. Natural adjuvants: endogenous activators of dendritic cells. Nat Med. 1999;5:1249-1255. https://doi.org/10.1038/15200
  18. Thery C, Amigorena S. The cell biology of antigen presentation in dendritic cells. Curr Opin Immunol. 2001;13:45-51. https://doi.org/10.1016/S0952-7915(00)00180-1
  19. de Waal Malefyt R, Abrams J, Bennett B, Figdor CG, de Vries JE. Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med. 1991;174:1209-1220. https://doi.org/10.1084/jem.174.5.1209
  20. Fiorentino DF, Zlotnik A, Mosmann TR, Howard M, O'Garra A. IL-10 inhibits cytokine production by activated macrophages. J Immunol. 1991;147:3815-3822.